Hamed Jafarpour

Hamed Jafarpour

Auto-generated profile, based on publicly available information

Hamed Jafarpour

Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2021 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
RGRoya Ghasemian
Roya Ghasemian
ASAmir Shamshirian
Amir Shamshirian
KHKeyvan Heydari
Keyvan Heydari
MMMohammad Malekan
Mohammad Malekan
RAReza Alizadeh-Navaei
Reza Alizadeh-Navaei
DSDanial Shamshirian
Danial Shamshirian

24 May 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
OTOmid Reza Tamtaji
Omid Reza Tamtaji
MBMohammad Behnam
Mohammad Behnam
MPMohammad Ali Pourattar
Mohammad Ali Pourattar
HJHamed Jafarpour
Hamed Jafarpour
ZAZatollah Asemi
Zatollah Asemi

6 June 2018 in Experimental and Therapeutic Medicine
Verified
Journal Article
Closed access
PDF file
LDLotfollah Davoodi
Lotfollah Davoodi
BMBabak Masoum
Babak Masoum
MMMahmood Moosazadeh
Mahmood Moosazadeh
HJHamed Jafarpour
Hamed Jafarpour
MHMohammad Reza Haghshenas
Mohammad Reza Haghshenas
TMTahoora Mousavi
Tahoora Mousavi
An estimated 185 million people worldwide are infected with hepatitis C virus (HCV). Combination therapy with pegylated interferon‑α (peg IFN) and ribavirin is the first line of treatment against the psychiatric side effects, including mood disorders, anxiety and irritability. In the present study, all of the studies electronically published between 2000 and 2016 were retrieved using databases including Scopus, PubMed, Institute for Scientific Information, Science Direct and Google Scholar. All of the articles were independently evaluated by two reviewers and the results were compared, followed by removal of duplicate, irrelevant and re‑published studies after reviewing. The studies were assessed based on the heterogeneity of their results using the Cochrane test and I2 analysis. All groups included neuropsychiatric side effects, fatigue was reported at the highest rate in 60.41% [95% confidence interval (CI)=39.18‑81.64%] and insomnia was reported at a lower rate in 16.28% of cases (95% CI=6.59‑25.98%). In conclusion, the present meta‑analysis indicated that treatment with peg IFN + ribavirin or interferon only is associated with a wide range of neuropsychiatric side effects, including fatigue, mood disorders, anxiety, irritability, emotional ability and agitation.

1 June 2020 in Oxford Medical Case Reports
Verified
Journal Article
Open access
PDF file
LDLotfollah Davoodi
Lotfollah Davoodi
HJHamed Jafarpour
Hamed Jafarpour
AKArmaghan Kazeminejad
Armaghan Kazeminejad
ESEissa Soleymani
Eissa Soleymani
ZAZahra Akbari
Zahra Akbari
ARAlireza Razavi
Alireza Razavi
The international outbreak of respiratory illness termed coronavirus disease 2019 (COVID-19) began in December 2019 that has affected >0.8 million individuals. Self-limiting respiratory tract involvement, severe pneumonia, multiorgan failure and death are the spectrum of COVID-19. To date, there are no especial therapeutic agents for COVID-19 infections. One such medication includes the antimalarial hydroxychloroquine (HCQ), which recently reported as a possible therapy for shortening the duration of COVID-19 symptoms, reducing inflammatory reactions to infection, impairing the exacerbation of pneumonia and boosting lung imaging findings. Like all medications, HCQ has side effects and may occur in COVID-19 patients. Here, we report on the case of a 42-year-old woman, presented with fever and dry cough, who had COVID-19 and 2 days later presented with a pruritic erythematous maculopapular rash, which started from the distal of upper extremities and rapidly, involved the entire body.

20 April 2020 in medRxiv
Verified
Preprint
Open access
PDF file
DSDanial Shamshirian
Danial Shamshirian
AHAmirhossein Hessami
Amirhossein Hessami
KHKeyvan Heydari
Keyvan Heydari
RAReza Alizadeh-Navaei
Reza Alizadeh-Navaei
MEMohammad Ali Ebrahimzadeh
Mohammad Ali Ebrahimzadeh
DSDanial Shamshirian
Danial Shamshirian
Background: Coronavirus Disease 2019 (COVID-19) has become a major global issue with rising the number of infected individuals and mortality in recent months. Among all therapeutic approaches, arguments have raised about hydroxychloroquine (HCQ) efficacy in the treatment of COVID-19. We carried out a systematic review and meta-analysis overcome the controversies regarding the effectiveness of hydroxychloroquine in the treatment of COVID-19. Methods: A systematic search was performed in PubMed, Scopus, Embase, Cochrane Library, Web of Science, Google Scholar and medRxiv pre-print database using all available MeSH terms for COVID-19 and hydroxychloroquine up to July 19, 2020. Studies focused on the effectiveness of HCQ with/without azithromycin (AZM) in confirmed COVID-19 patients were entered into the study. Two researchers have independently evaluated quality assessment of the studies and abstracted data for data extraction. Extracted data were analyzed using CMA v . 2.2.064. Heterogeneity was assessed using the I -squared ( I 2 ) test, and fixed/random-effects model was used when appropriate for pooling of studies. Results: Out of 26 studies entered into our systematic review, 21 studies including 14 comparative studies with control group and seven observational studies containing 103,486 participants have entered into the meta-analysis. The results of the meta-analysis on comparative studies indicated no significant clinical effectiveness (negative in RT-PCR evaluation) for HCQ regimen in the treatment of COVID-19 in comparison to control group (RR: 1.03, 95% CI, 0.79-1.34). The same result was observed for the combination of HCQ+azithromycin (RR: 1.26, 95% CI, 0.91-1.74). No significant differences were found for both HCQ (RR: 0.92, 95% CI, 0.72-1.16) and HCQ+AZM (RR: 1.72, 95% CI, 0.86-3.42) mortality rate; however, mortality was affected by age differences according to meta-regression analysis (P<0.000001). No substantial difference was observed for disease exacerbation (RR: 1.23, 95% CI, 0.65-2.30) between HCQ group and controls. Also, radiological findings significantly improved in the HCQ group (OR: 0.32, 95% CI, 0.11-0.98). Odds of known HCQ adverse effects (diarrhea, vomiting, blurred vision, rash, headache, etc.) occurred in the HCQ regimen group was approximately 3.5 times of control group (OR: 3.40, 95% CI, 1.65-6.98), but no substantial differences were found regarding intubation odds between HCQ group and control group (OR: 2.11, 95% CI, 0.31-14.03). Meta-analysis indicated no significant prophylactic effects for HCQ (OR: 0.40, 95% CI, 0.04-3.65) Conclusion: This systematic review and meta-analysis showed no clinical benefits regarding HCQ treatment with/without azithromycin for COVID-19 patients. Although mortality rate was not significantly different between cases and controls, frequency of adverse effects was substantially higher in HCQ regimen group. However, due to that most of the studies were non-randomized and results were not homogenous, selection bias was unavoidable and further large randomized clinical trials following comprehensive meta-analysis should be taken into account in order to achieve more reliable findings. Also, it is worth mentioning that if this work does not allow to quantify a “value” of the HCQ, it allows at least to know what is not the HCQ and that it would be prudent not to continue investing in this direction.

1 March 2024 in Asian Journal of Neurosurgery
Verified
Journal Article
Open access
PDF file
KHKaveh Haddadi
Kaveh Haddadi
SASaeed Abediankenari
Saeed Abediankenari
SESaeed Ehteshami
Saeed Ehteshami
AAAbbas Alipour
Abbas Alipour
HMHassan Shayan Majd
Hassan Shayan Majd
LALeila Asadian
Leila Asadian
Introduction The role of some biomarkers such as S100 beta (S100B) has been somewhat known in determining the severity of primary acute spinal cord injury (SCI), and today, it has been the basis of various relevant studies. Therefore, this study estimates the S100B level in serum and cerebrospinal fluid (CSF) in patients with spinal injuries. Methods This was a descriptive-analytic study. In this study, 31 patients with acute SCI referred to Sari Imam Khomeini Hospital, Iran, were recruited. Patients were divided into two groups of complete and incomplete SCI according to the American Spinal Injury Association (ASIA). The S100B concentrations in serum and CSF levels were compared between the two groups. Result There was only significant positive correlation between S100B CSF concentration and complete SCI based on the ASIA criterion, meaning that in cases of complete SCI the S100B CSF concentration was significantly increased correlation coefficient (CC) (cc = 0.529 and p = 0.002). Based on the results of serum S100B protein concentration, 14.70 ng/dL with a sensitivity of 66.7% and specificity of 55% was determined as cutoff for complete SCI. Also, about the CSF S100B protein level variable, concentration of 342.18 ng/dL with 100% sensitivity and 64% specificity was determined as cutoff for complete injury. Conclusion The results of this unique study have shown that S100B were useful markers for predicting the prognosis of patients with acute SCI and cutoff points determined for serum and especially CSF concentrations can differentiate complete and incomplete SCI.